Prognostic Significance of Bone Metastases and Bisphosphonate Therapy in Patients with Renal Cell Carcinoma》.pdf

E U R O P E A N U R O L O G Y 6 6 ( 2 0 1 4 ) 5 0 2 – 5 0 9 availa ble at www.scien ced journal homepage: Platinum Priority – Kidney Cancer Editorial by Janet E. Brown and Steven L. Wood on pp. 510–511 of this issue Prognostic Significance of Bone Metastases and Bisphosphonate Therapy in Patients with Renal Cell Carcinoma Rana R. McKay a, Xun Lin b, Julia J. Perkins b, Daniel Y.C. Heng c, Ronit Simantov b, Toni K. Choueiri a, * a Dana-Farber Cancer Institute, Boston, MA, USA; b Pfizer Oncology, New York, NY, USA; c Tom Baker Cancer Center, Calgary, Alberta, Canada Article info Abstract Article history: Background: Bone metastases (BMs) are frequently present in patients with metastatic Accepted February 17, 2014 renal cell carcinoma (mRCC) and cause significant morbidity. Published online ahead of Objective: The purpose of this analysis was to assess the impact of BMs and bispho- sphonate therapy (BT) on outcomes in mRCC. print on February 26, 2014 Design, setting, and participants: We conducted a pooled analysis of patients with mRCC treated from 2003 to 2011 in phase 2 and 3 trials. Keywords: Outcome measurements and statistical analysis: Statistical analyses were performed Bisphosphonates using Cox regression and the Kaplan-Meier method. Results and limitations: We identified 2749 patients treated with sunitinib (n = 1059), Bone metastases sorafenib (n = 355), axitinib (n = 359), temsirolimus (n = 208), temsirolimus plus inter- mTOR inhibitors